Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-FU and Imiquimod for High-Grade Cervical Squamous Intraepithelial Lesions
NCT03196180Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2019
- Primary completion
- Nov 2020
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fluorouracil 5% cream and imiquimod in cervical intraepithelial neoplasia (CIN), sponsored by National Cancer Institute. Primary endpoint: Feasibility of Intravaginal Use 5-FU and Imiquimod at 22 weeks. Started Oct 2019; status: completed.
02
Drugs
fluorouracil 5% creamimiquimod
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT03196180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03196180.